Literature DB >> 6833759

Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia.

W J Britt, B Chesebro.   

Abstract

During the course of progressive Friend virus-induced leukemia in Rfv-3r/s mice, antiviral antibody caused a marked reduction in the frequency of leukemic spleen cells releasing infectious virus. We investigated the mechanism of this antibody-induced alteration of leukemia cell phenotype in a series of passive transfer experiments using monoclonal antiviral antibodies. Our results indicated that two IgG2a anti-gp70 cytotoxic antibodies could reduce the frequency of virus-producing cells within the leukemic spleen as well as maintain the virus-nonproducing phenotype once it was established. IgG2a and IgG2b monoclonal anti-p 15 antibodies, IgM, and IgA anti-gp70 antibodies, and an IgG3 anti-p 15(E) antibody were not effective. The mechanism of this phenotypic alteration appeared to involve an antibody-mediated cytostasis of virus-producing leukemia cells with the subsequent over-growth of virus-nonproducing cells. The maintenance of the virus-nonproducing phenotype was dependent on the presence of anti-gp70 antibodies capable of neutralizing and clearing infectious F-MuLV in vivo. The presence of these neutralizing antibodies appeared to prevent reinfection of virus-nonproducing cells and therefore interfered with reversion to the virus-producing phenotype.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6833759

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

2.  Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Authors:  Laurent Gros; Hanna Dreja; Anne Laure Fiser; Marc Plays; Mireia Pelegrin; Marc Piechaczyk
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  Requirement for Fc effector mechanisms in the APOBEC3/Rfv3-dependent neutralizing antibody response.

Authors:  Kalani Halemano; Bradley S Barrett; Karl J Heilman; Thomas E Morrison; Mario L Santiago
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

5.  Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

Authors:  S H Pincus; R Cole; R Ireland; F McAtee; R Fujisawa; J Portis
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Authors:  U Dittmer; K E Peterson; R Messer; I M Stromnes; B Race; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Protection against establishment of retroviral persistence by vaccination with a live attenuated virus.

Authors:  U Dittmer; D M Brooks; K J Hasenkrug
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor.

Authors:  Mario L Santiago; Diana S Smith; Bradley S Barrett; Mauricio Montano; Robert L Benitez; Roberta Pelanda; Kim J Hasenkrug; Warner C Greene
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

9.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.

Authors:  K J Hasenkrug; D M Brooks; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

Review 10.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.